Ozempic Price by Country: GLP-1 International Pricing Comparison

Disclosure: The RX Index has affiliate relationships with some U.S. telehealth companies. This research page contains no affiliate links and uses the source hierarchy described in the Methodology section below.

For anyone searching Ozempic price by country, here’s the short version: Ozempic and Wegovy cost a lot more at U.S. list price than in the UK, Canada, France, Australia, and many European markets — but the size of the gap depends entirely on which “price” you mean. A U.S. manufacturer list price is not the same thing as a UK NHS list price, an Ontario drug benefit price, or an Australian PBS patient charge. This page tracks all three layers — manufacturer list, public payer price, and patient out-of-pocket — for every country where we have a verified primary source.

Quick answer: GLP-1 prices by country (May 2026)

Same month of medication. Six countries. Six very different numbers.

FX conversions: ECB reference rates May 7, 2026 (EUR/USD 1.1770; GBP/EUR 0.86410; CAD/EUR 1.6040; AUD/EUR 1.6219; MXN/EUR 20.2473). Sources and full notes per row are in the master table and country drilldowns below.

The master comparison table

Each row carries the country, drug, dose or pack, native price, USD equivalent, price type, source, last-verified date, and a comparability flag.

Ozempic — international price comparison (May 7, 2026)

Wegovy — international price comparison (May 7, 2026)

Pending primary-source verification (not used in charts, rankings, or schema)

These rows have been collected from authoritative secondary reporting but have not yet been confirmed against a current primary-source capture.

These will move into the main tables in the next refresh once we have primary-source documentation.

Why these GLP-1 prices are not directly comparable

The price types we use, defined

Dose and pack size aren’t interchangeable

A 0.25 mg starter pack is not a 2.4 mg maintenance pack. Wegovy in the UK is £73.25 for the starter pack and £175.80 for the maintenance pack — both are NICE list prices, but they’re not comparable to each other, let alone to a U.S. monthly figure. We label the dose on every row.

FX conversions can mislead

We show local currency first, then a date-stamped USD conversion. Conversions use European Central Bank reference rates from the verification date — May 7, 2026. The ECB notes its rates are reference rates published for indicative purposes, not transaction rates. They don’t reflect pharmacy spreads, card fees, taxes, or VAT differences. Local prices remain the primary data; converted prices are rounded and provided for comparison only. Source: European Central Bank — Euro foreign exchange reference rates.

Confidential discounts make the “real” UK and Canada prices invisible

NICE notes a “commercial arrangement” for Wegovy on the NHS in TA875 — meaning the NHS likely pays less than £175.80, but the actual net price isn’t public. Treat list prices in those countries as the ceiling of what the public system pays, not the floor.

How we flag comparability per row

Ozempic price by country

Ozempic price in the United States

Last verified: May 7, 2026 · NovoCare lists Ozempic at $1,027.51 per package (manufacturer list price). NovoCare itself defines list price as the price before insurance, rebates, or discounts. Most insured Americans pay much less:

• Commercial insurance + savings card: as low as $25/month for eligible patients (subject to maximum savings and restrictions)
• NovoCare self-pay program: $349/month for 0.25–1 mg, $499/month for 2 mg
• TrumpRx self-pay (launched February 5, 2026): approximately $350/month average; “as low as $199” by dosage
• Medicare / state Medicaid (MFN price): $245/month
• Medicaid for type 2 diabetes: typical low copay structure under standard Medicaid drug pricing rules; varies by state

Source: NovoCare Ozempic list-price page; White House TrumpRx fact sheet, Feb 5, 2026; White House MFN fact sheet, Nov 6, 2025.

Ozempic price in the UK

Last verified: May 7, 2026 · The British National Formulary (BNF) lists semaglutide medicinal forms at £73.25 per pack. The NHS prescription charge for the patient in England is £9.90 per item, and prescriptions are free in Scotland, Wales, and Northern Ireland. Ozempic is prescribed on the NHS for type 2 diabetes, not for weight loss; the weight-loss-indicated semaglutide product is Wegovy.

Source: BNF — Semaglutide medicinal forms; NHSBSA Drug Tariff (May 2026).

Ozempic price in Canada

Last verified: May 7, 2026 · Canadian drug pricing is layered. Each province runs its own public formulary; the Patented Medicine Prices Review Board (PMPRB) reviews patented medicine prices to protect Canadians from excessive pricing — PMPRB does not set drug prices in Canada. The Ontario Drug Benefit (ODB) lists Ozempic at C$227.94 with limited-use coverage.

The bigger 2026 story: Health Canada approved Dr. Reddy’s generic semaglutide injection on April 28, 2026, and Apotex’s generic semaglutide injection on May 1, 2026. Health Canada notes that many generic medications in Canada are 45% to 90% cheaper than brand-name versions. We have not yet verified a current pharmacy or formulary price for generic semaglutide in Canada — that gets added on the next refresh once primary-source pricing is published.

Source: Ontario Formulary; PMPRB; Health Canada — Canada becomes the first G7 country to approve a generic version of semaglutide.

Ozempic price in France

Last verified: May 7, 2026 · France’s official public medicines database lists Ozempic 1 mg at €77.60 including the dispensing honorarium, with a 30% reimbursement rate by Assurance Maladie for eligible diabetes indications.

Source: Base de Données Publique des Médicaments — Ozempic, last updated April 28, 2026.

Ozempic price in Australia

Last verified: May 7, 2026 · The Pharmaceutical Benefits Scheme (PBS) lists Ozempic with a Dispensed Price for Maximum Quantity (DPMQ) of A$134.60. The general patient charge is A$25 per script; concession card holders pay A$7.70. Authority required, restricted to type 2 diabetes — Ozempic is not PBS-listed for weight management in Australia.

Source: PBS Schedule — Ozempic.

Ozempic price in Mexico

Last verified: May 7, 2026 · Mexico operates a retail-first pricing model for Ozempic. Retail prices observed across COFEPRIS-licensed pharmacy chains:

• Farmacias del Ahorro: MX$5,847 list / MX$4,385.25 with a 25% online discount
• Farmacia Prixz: MX$5,150 for the 1.34 mg/mL, 3 mL pen
• Farmacia San Pablo: MX$3,000–5,500+ depending on dose and location

Approximate USD range: $180–$337/month at the May 7, 2026 ECB rate.

Source: COFEPRIS sanitary registry and alerts; Farmacias del Ahorro, Prixz, San Pablo retail pages; WHO Medical Product Alert No. 2/2024.

Wegovy price by country

Wegovy price in the United States

Last verified: May 7, 2026 · NovoCare lists Wegovy at $1,349.02 per package (manufacturer list price). Patient out-of-pocket varies enormously:

• With insurance + savings card: as low as $0–$25/month for eligible commercial-insurance patients (government beneficiaries excluded)
• NovoCare self-pay (0.25–2.4 mg): $349/month; Wegovy HD self-pay $399/month
• TrumpRx (launched February 5, 2026): ~$350/month average; “as low as $199” by dosage
• Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027): $50/month patient copay for eligible Medicare Part D beneficiaries; $245 net price per monthly supply
• Medicare / state Medicaid (MFN): $245/month negotiated price

Bridge eligibility criteria: BMI ≥35; or BMI ≥30 with HFpEF, uncontrolled hypertension, or CKD stage 3a or above; or BMI ≥27 with prediabetes, prior myocardial infarction, prior stroke, or symptomatic peripheral artery disease.

Source: NovoCare Wegovy; CMS Medicare GLP-1 Bridge; White House TrumpRx fact sheet.

Wegovy UK price (NICE list prices)

Last verified: May 7, 2026 · NICE TA875 lists the following pack prices, also reflected in the BNF:

• Wegovy 2.4 mg / pack: £175.80
• Wegovy 1.7 mg / pack: £124.53
• Wegovy 0.25 mg, 0.5 mg, 1.0 mg / pack: £73.25

NICE notes a confidential commercial arrangement with the NHS. Patient cost within NHS-funded specialist weight management services is the standard NHS prescription charge: £9.90 per item in England, free in Scotland, Wales, and Northern Ireland.

Most current UK Wegovy patients access the medication through private prescription routes, with private monthly costs reported in the £100–£300 range depending on dose and provider. We carry these as authoritative-secondary observations, not primary government data.

NICE published TA1152 on May 7, 2026 — the day of this verification — recommending semaglutide for reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity. NHS England’s April 1, 2026 draft announcement estimated 1.2 million people could become eligible.

Source: NICE TA875 — Section 2; NICE TA1152 (published May 7, 2026); UK regulated-pharmacy reporting (Bolt Pharmacy, medino, Second Nature) for access and private-pricing context.

Wegovy price in Canada

Last verified: May 7, 2026 · The Canadian Drug Agency (CDA-AMC) issued a final recommendation for Wegovy reimbursement that assumed an expected cost of approximately C$5,066 per patient per year (~C$422/month) and required a price reduction for cost-effectiveness. Provincial coverage varies.

Source: CDA-AMC — Semaglutide (Wegovy) Final Recommendation.

Wegovy in Germany, France, Denmark, and the Netherlands

These rows are pending primary-source verification. Reported figures from wire reporting:

• Germany: ~€301.91 / 4 weeks at highest dose (Reuters). German law generally excludes weight-management drugs from Statutory Health Insurance reimbursement under the SGB V framework.
• France: ~€274–€365/month private launch price (Le Monde). Assurance Maladie does not generally reimburse Wegovy for weight management.
• Denmark: DKK 1,313 (starter) to DKK 2,353 (maintenance) per month (Reuters). Public health care does not generally reimburse weight-loss drugs.
• Netherlands: ~€328 (Peterson-KFF historic baseline). Awaiting current GVS database capture.

Mounjaro and Zepbound — a short U.S. note

Tirzepatide (Mounjaro for type 2 diabetes; Zepbound for chronic weight management) carries similar U.S. pricing dynamics to semaglutide, but international tirzepatide rows are still in primary-source verification. Verified for the U.S. on this snapshot:

• Mounjaro / Zepbound list price (U.S.): ~$1,080/month (Lilly direct-to-patient pricing)
• TrumpRx Zepbound (launched Feb 5, 2026): ~$350/month average; “as low as $199” by dosage
• Medicare / state Medicaid MFN: $245/month negotiated price
• Medicare GLP-1 Bridge (Zepbound KwikPen): $50/month patient copay; July 1, 2026 – December 31, 2027

For a verified UK reference point: Superdrug Online Doctor reports Mounjaro to the NHS at £122/month at maintenance dose (15 mg/week), reflecting the NHS-negotiated supply price for the phased rollout through 2026–2027. Carried as authoritative-secondary; primary NHS contract pricing is not public.

A standalone international tirzepatide table will publish once primary-source international rows clear verification.

What changed in 2026: MFN, TrumpRx, the Medicare GLP-1 Bridge, and the generic wave

The Most-Favored-Nation (MFN) framework

President Trump signed agreements with Novo Nordisk and Eli Lilly on November 6, 2025. Headline numbers:

• Medicare and state Medicaid: $245/month for injectable GLP-1s (Ozempic, Wegovy, Mounjaro, Zepbound). All 50 state Medicaid programs have access to MFN prices.
• TrumpRx self-pay (launched February 5, 2026): ~$350/month average for injectable GLP-1s; “as low as $199” by dosage strength
• Oral GLP-1s on TrumpRx: ~$149 starter dose
• Medicare obesity coverage: for the first time, Medicare covers certain GLP-1s for weight reduction in eligible patients via the GLP-1 Bridge demonstration

The White House Council of Economic Advisers (May 5, 2026 report) estimated $529B in 10-year domestic savings from prospective MFN pricing and an additional $64.3B in federal and state savings from applying MFN pricing to existing Medicaid drugs. These are administration estimates, not independently verified savings.

What MFN does not cover: commercial employer-sponsored insurance, the uninsured outside TrumpRx, and most existing patient-assistance program structures.

Source: White House TrumpRx fact sheet (Feb 5, 2026); White House MFN fact sheet (Nov 6, 2025); White House CEA report (May 5, 2026).

The Medicare GLP-1 Bridge

The Bridge is a CMS demonstration running July 1, 2026 through December 31, 2027. Eligible Medicare Part D beneficiaries pay a $50 patient copay per monthly supply. Participating manufacturers provide eligible drugs at a $245 net price per monthly supply.

CMS currently lists the following as Bridge-eligible products when used for weight reduction:

• Wegovy injection
• Wegovy tablets
• Foundayo (orforglipron, FDA-approved April 1, 2026)
• Zepbound KwikPen

Source: CMS — Medicare GLP-1 Bridge; CMS — $50 monthly access press release.

The 2026 generic semaglutide wave (outside the U.S.)

This is the most under-covered drug-pricing story of 2026.

• Canada: Novo Nordisk allowed regulatory exclusivity to expire January 4, 2026. Health Canada approved Dr. Reddy’s generic semaglutide on April 28, 2026, and Apotex’s generic on May 1, 2026. Health Canada notes generics are commonly 45% to 90% cheaper than brand-name versions.
• India: Generic semaglutide launched commercially in March 2025.
• Worldwide: A March 2026 medRxiv preprint identified 10 countries where semaglutide patents expire in 2026, with broader generic distribution projected through year-end.

Not the United States. Novo Nordisk’s U.S. patent portfolio — built around delivery-device innovation, not just the molecule — keeps semaglutide protected in the U.S. through approximately 2033. So the 2026 generic wave widens the U.S.-international gap on the international side, even as MFN narrows it on the U.S. side.

Source: Health Canada — Canada becomes the first G7 country to approve a generic version of semaglutide; subsequent Apotex approval reporting; medRxiv preprint (Barber et al., March 2026).

The 2027 U.S. list-price reduction

Novo Nordisk has announced (Reuters, February 24, 2026) that effective January 1, 2027:

• Wegovy U.S. list price will fall 50%
• Ozempic U.S. list price will fall 35%
• Affected products move to ~$675/month
• Self-pay and direct-to-patient pricing is unaffected

Source: Reuters — Novo Nordisk to halve US list price of Wegovy from 2027.

Production cost vs. sticker price

A 2024 study published in JAMA Network Open (Barber, Gotham, Bygrave, Cepuch et al., Yale School of Medicine) estimated cost-based prices of $0.75 to $72.49 per month across GLP-1 agonists as a class. For injectable semaglutide specifically, the study estimated $0.89 to $4.73 per month — compared with the lowest market prices the authors found of $38.21 to $353.74 per month. These estimates include manufacturing cost plus a profit margin and tax allowance; they don’t represent a “fair” price, but they anchor the cost floor in the debate.

Source: JAMA Network Open — Estimated Sustainable Cost-Based Prices for Diabetes Medicines.

GLP-1 price US vs Europe — three side-by-side views

The U.S.-vs-Europe gap is real at the list-price layer. It shrinks dramatically when you switch to the right comparison column. We show three views.

View 1: U.S. list price vs. official foreign prices

Note: these are all different price types. France = official public pharmacy price (30% reimbursement, diabetes). Australia = PBS DPMQ. UK = BNF tariff. Canada = Ontario Drug Benefit, limited use. All require specific eligibility. Compare within a column only.

View 2: U.S. government / self-pay prices vs. official foreign prices

View 3: U.S. patient cost with savings card vs. international patient copays

Why is Ozempic cheaper in Canada?

Public drug-benefit pricing

Each Canadian province runs its own public drug formulary. Ontario, Quebec (RAMQ), British Columbia (PharmaCare), and others negotiate or list prices for drugs they reimburse. Those listed prices are bound by clinical eligibility (typically type 2 diabetes with specified conditions), not an open-market retail price.

PMPRB context

The Patented Medicine Prices Review Board reviews patented medicine prices in Canada to protect Canadians from excessive pricing. PMPRB does not set drug prices in Canada. PMPRB’s framework references international prices and applies guidelines that constrain how high patented drugs can launch. Combined with provincial formulary negotiation, this is most of the reason Canadian list prices land where they do.

The 2026 generic semaglutide wave

• January 4, 2026: Novo Nordisk’s regulatory exclusivity for semaglutide expired in Canada
• April 28, 2026: Health Canada approved Dr. Reddy’s generic semaglutide injection (the first generic semaglutide in any G7 country)
• May 1, 2026: Health Canada approved Apotex’s generic semaglutide injection

Canadian Ozempic pricing in 2026 is entering a generic-competition phase, while U.S. list prices stay protected by patent through approximately 2033.

Wegovy NHS cost: the public number vs. the real number

The visible list prices (NICE TA875)

• Wegovy 2.4 mg / pack: £175.80
• Wegovy 1.7 mg / pack: £124.53
• Wegovy 0.25 mg, 0.5 mg, 1.0 mg / pack: £73.25

Source: NICE TA875 — Section 2.

The confidential commercial arrangement

NICE explicitly notes that semaglutide is available to the NHS with a discount, the details of which are confidential. That means the visible list price is the ceiling of what the NHS pays — not the actual contract price.

Patient out-of-pocket on the NHS

Through an NHS Tier 3 specialist weight management service in England, the patient cost is the standard NHS prescription charge — £9.90 per item (May 2026). In Scotland, Wales, and Northern Ireland, NHS prescriptions are free.

The NHS access bottleneck is real. UK regulated pharmacy reporting from Bolt Pharmacy, medino, Second Nature, and other licensed providers describes Tier 3 specialist weight management waiting lists commonly running 12–24 months by region, with some integrated care boards pausing new initiations during supply constraints.

Cardiovascular indication added May 7, 2026

NICE published TA1152 on May 7, 2026 recommending semaglutide for reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity. NHS England’s April 1, 2026 announcement estimated 1.2 million people could become eligible. The new indication doesn’t add specialist-service capacity, so NHS access pressure remains active even as eligibility expands.

Source: NICE TA1152; NHS England April 1, 2026 announcement.

Cheapest verified Ozempic — and why “cheapest country” is a trap

Cheapest verified primary-source rows (Ozempic, May 7, 2026)

1. France — €77.60 (~$91) — Official public pharmacy price, 30% reimbursement (diabetes)
2. Australia — A$134.60 DPMQ (~$98) — PBS dispensed price; A$25 general patient charge
3. UK — £73.25 (~$100) — BNF / NHSBSA tariff-style price; £9.90 prescription charge
4. Canada (Ontario) — C$227.94 (~$167) — Ontario Drug Benefit, limited use

Cheapest verified patient-cost rows

1. Australia PBS — A$7.70 concession (~$5)
2. UK NHS (Scotland/Wales/NI) — Free
3. UK NHS (England) — £9.90 per item (~$13)
4. Australia PBS general — A$25 (~$18)
5. U.S. with savings card and commercial insurance — as low as $25 (eligibility rules apply)

Why the ranking misleads

• Different indications: France’s 30% reimbursement applies to type 2 diabetes; not weight management.
• Different price types: UK BNF figure is a tariff price, not a payer net price.
• Different access conditions: PBS authority required; Ontario limited-use; Tier 3 service-gated NHS Wegovy.
• Confidential rebates: The UK net Wegovy price is below £175.80 — we just don’t know by how much.
• Retail vs. official: Mexico is retail-only, included for pricing context only, with active counterfeit alerts.

The “cheapest country” framing generates clicks; the “cheapest verified price within a labeled price type” framing survives an editor’s review.

Can Americans buy cheaper Ozempic from Canada or Mexico?

What FDA says about personal importation

FDA states that in most circumstances it is illegal for individuals to import drugs into the U.S. for personal use, and recommends obtaining medicines from legal U.S. sources. FDA’s personal importation policy is a narrow enforcement-discretion framework for limited situations — not a general authorization.

Source: FDA — Personal Importation.

Why Canadian and Mexican pharmacies are pushing back

In 2023, a single Texas physician reportedly wrote roughly 17,000 prescriptions over three months that were filled at British Columbia online pharmacies and shipped to U.S. addresses — about 15% of all Ozempic prescriptions filled in BC for that period. Nova Scotia’s health minister announced restrictions on sales to non-Canadians shortly after. BC followed. The cross-border buying loophole is closing.

Counterfeit risk and product-specific storage

The WHO issued Medical Product Alert No. 2/2024 covering falsified Ozempic batches identified in Brazil, the U.K., and the U.S. COFEPRIS has issued multiple alerts about illegally marketed Ozempic in Mexico (most recently April 2026).

Storage risk is product-specific. Ozempic is refrigerated before first use and can be stored at controlled room temperature for up to 56 days after first use. Wegovy injection is refrigerated and may be kept at 46°F–86°F for up to 28 days before cap removal. This page is not importation advice.

Source: Novo Nordisk — Storage and stability for GLP-1 RAs.

Legitimate alternatives for U.S. patients

• Manufacturer savings cards: commercial insurance + savings card brings Ozempic and Wegovy out-of-pocket as low as $25/month for eligible patients
• NovoCare self-pay: $349/month for Ozempic 0.25–1.0 mg; $349/month for Wegovy 0.25–2.4 mg
• TrumpRx (launched February 5, 2026): ~$350/month average for injectables; “as low as $199” by dosage
• Medicare GLP-1 Bridge (July 1, 2026): $50/month copay for eligible Medicare beneficiaries (Wegovy, Foundayo, Zepbound KwikPen)
• Medicare/state Medicaid under MFN: $245/month negotiated price
• Patient assistance programs (NovoCare PAP, Lilly Cares): free medication for eligible patients with income limits and no commercial insurance

Methodology

This is the part that earns the link. Every published row has a source URL, source type, capture date, last-verified date, and comparability flag.

Source hierarchy

We accept sources in this order. If a higher-tier source exists, we use it.

1. Official national formulary, drug tariff, or public medicine database (NHS BNF, NHSBSA Drug Tariff, Ontario Drug Benefit Formulary, Base de Données Publique des Médicaments France, PBS Schedule, MHLW NHI Drug Price List)
2. Government health technology assessment body (NICE TA, CDA-AMC, HAS, IQWiG, PBAC)
3. Manufacturer official list-price page (NovoCare, Lilly direct-to-patient pricing portals)
4. Public payer or reimbursement database (CMS, GKV-Spitzenverband, Ameli.fr)
5. Regulator notice or alert (FDA, MHRA, ANSM, COFEPRIS, WHO Medical Product Alerts)
6. Major wire service or reputable health-policy publication (Reuters, AP, Bloomberg, KFF Health News, STAT, AJMC)
7. Retail pharmacy snapshot (only when no higher-tier source exists, and always labeled as retail)

FX methodology

USD conversions use European Central Bank reference rates from the verification date — May 7, 2026 for this snapshot. Local prices remain the primary data; converted prices are rounded and provided for comparison only.

What we deliberately don’t do

• Purchasing power parity (PPP) adjustments — not in the headline table. PPP can make low-income-country prices look “expensive” and obscure the policy comparison.
• Averaging across countries — we show the row, the source, and the date. Averages hide more than they reveal.
• Compounded GLP-1 prices — covered separately.
• Grey-market or unverified online pharmacy prices — explicitly excluded.

Refresh schedule

Correction policy

See an outdated or wrong number? Email research@therxindex.com with the country, drug, source URL, date, and a screenshot. We review source-backed corrections and update the table within 7 business days, with the change recorded in our public change log.

What we actually verified

Three buckets, plainly labeled.

Verified from primary source

Verified from authoritative secondary source

Pending primary-source capture (not in master table or charts)

How to cite this page

We built this so you can use it. Three citation formats and a suggested caveat below.

No email gate. The data is public. Use it with attribution.

Frequently asked questions

Country-by-country data notes

United States

• List prices are public; net prices (after rebates) are mostly not
• The November 2025 MFN deals ($245 Medicare/Medicaid, ~$350 average TrumpRx self-pay) materially change the picture for a meaningful slice of U.S. patients
• Novo Nordisk has announced U.S. list-price reductions effective January 1, 2027: Wegovy down 50%, Ozempic down 35%; affected products at ~$675/month; self-pay and direct-to-patient pricing unaffected (Reuters)
• Medicare GLP-1 Bridge runs July 1, 2026 – December 31, 2027 with $50 patient copays; current Bridge product list is Wegovy, Foundayo, and Zepbound KwikPen — Ozempic is not currently on the Bridge list

United Kingdom

• NICE TA875 governs Wegovy weight management; TA1152 (published May 7, 2026) recommends semaglutide for cardiovascular indication
• Confidential commercial arrangement applies on the NHS
• NHSBSA Drug Tariff is updated monthly
• UK Mounjaro NHS rollout reportedly £122/month at maintenance — separate phased rollout through 2026–2027

Canada

• Provincial formularies vary; Ontario is the cleanest publicly listed example
• PMPRB reviews patented-drug prices for excessive pricing; does not set prices
• Health Canada approved Dr. Reddy’s generic semaglutide on April 28, 2026; Apotex on May 1, 2026 — major refresh trigger for current generic pricing
• BC and Nova Scotia have restricted sales to non-Canadians

France

• Base de Données Publique des Médicaments is the canonical source, updated regularly (last update April 28, 2026 for Ozempic 1 mg)
• Reimbursement is 30% for type 2 diabetes; weight management is not generally reimbursed
• Wegovy launched in France as a private, non-reimbursed medication

Australia

• PBS Schedule is updated monthly
• Authority required for Ozempic prescriptions
• Wegovy is not currently PBS-listed for weight management

Mexico

• Retail-only pricing for Ozempic
• COFEPRIS has issued multiple counterfeit alerts in 2024–2026
• Mexico row is included for pricing context only, not as a buying recommendation

Pending verification

• Germany, France Wegovy private, Denmark, Netherlands, Japan, Switzerland, Sweden — see Pending primary-source verification

Change log